Tango Therapeutics TNGX Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's other accrued liabilities?
- Tango Therapeutics (TNGX) reported other accrued liabilities of $1.56M in Q1 2026.
- How has Tango Therapeutics's other accrued liabilities changed year-over-year?
- Tango Therapeutics's other accrued liabilities decreased by 21.2% year-over-year, from $1.98M to $1.56M.
- What is the long-term trend for Tango Therapeutics's other accrued liabilities?
- Over 5 years (2020 to 2025), Tango Therapeutics's other accrued liabilities has grown at a 10.2% compound annual growth rate (CAGR), from $793K to $1.29M.